Protocol Ledger

NCT06683651 · Phase III · RECRUITING

A Study in Chinese Patients With Acquired Blepharoptosis

Interventional Phase III clinical trial protocol NCT06683651 sponsored by Santen Pharmaceutical Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-22 Enrollment: 180 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06683651
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)180 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06683651
Protocol FieldVerified Registry Value
NCT IdentifierNCT06683651
Consolidated Lead SponsorSanten Pharmaceutical Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment180 participants (ESTIMATED)
Registered Start Date2024-10-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI